Abalone Bio is a seed-stage GPCR antibody therapeutics platform company, first focusing on meeting unmet needs in fibrosis, neuropathic pain, polycystic kidney disease, and rare cancers. Abalone Bio has developed a functional GPCR antibody discovery platform with the unique ability to find ultra-rare modulators- not just blockers- of GPCR function, such as agonists. Its first preclinical-stage antibody candidate is a potent and selective agonist of a human cannabinoid receptor with applicability in a number of indications. Abalone Bio is an NSF Phase I and Phase II SBIR awardee.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
cannabinoid receptor antibody agonist
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):